Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 3/20 | 0.48 |
| ▸ | POLB | P06746 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | GAA | P10253 | 2/20 | 0.48 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.44 |
| ▸ | MERTK | Q12866 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | IDO1 | P14902 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | APAF1 | O14727 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | BLM | P54132 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3720122 | 0.95 | EPHX1 (0.55) | EPHX1MAPTPOLBLMNAGAA | |
| SCHEMBL2466559 | 0.93 | EPHX1 (0.58) | EPHX1MAPTPOLBLMNAGAA | |
| SCHEMBL16961161 | 0.88 | EPHX1 (0.53) | EPHX1MAPTPOLBLMNAGAA | |
| 4-Aminophenol SCHEMBL2890947 | 0.85 | GAA (0.53) | EPHX1MAPTPOLBLMNAGAA | |
| SCHEMBL28626293 | 0.83 | EPHX1 (0.41) | EPHX1MAPTPOLBLMNAGAA | |
| SCHEMBL11526739 | 0.83 | MAPT (0.63) | MAPTPOLBLMNAGAANPC1 | |
| SCHEMBL2247061 | 0.81 | PDK2 (0.47) | EPHX1MAPK1PDK2 | |
| SCHEMBL657242 | 0.81 | MAPK1 (0.44) | EPHX1MAPTPOLBLMNAGAA | |
| SCHEMBL3400048 | 0.80 | MAPT (0.61) | EPHX1MAPTPOLBLMNAGAA | |
| SCHEMBL78145 | 0.80 | MAPT (0.61) | EPHX1MAPTPOLBLMNAGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110023297-A | SUBSTITUTED HYDANTOIN AND THIOHYDANTOIN DERIVATIVES AS ANDROGEN RECEPTOR ANTAGONISTS | 詹森药业有限公司 | 2019-07-16 | — | — | CN | disclosed |
| CN-102438988-B | Resorcinol derivatives as hsp90 inhibitors | NERVIANO MEDICAL SCIENCES SRL | 2015-06-24 | — | — | CN | disclosed |
| US-8993556-B2 | Resorcinol derivatives as HSP90 inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2015-03-31 | — | — | US | disclosed |
| EP-2421833-B1 | RESORCINOL DERIVATIVES AS HSP90 INHIBITORS | NERVIANO MEDICAL SCIENCES SRL (IT) | 2015-01-14 | — | — | EP | disclosed |
| EP-2421833-A1 | RESORCINOL DERIVATIVES AS HSP90 INHIBITORS | Nerviano Medical Sciences S.r.l. (IT) | 2012-02-29 | — | — | EP | disclosed |
| US-20120046266-A1 | RESORCINOL DERIVATIVES AS HSP90 INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2012-02-23 | — | — | US | disclosed |
| WO-2010121963-A1 | RESORCINOL DERIVATIVES AS HSP90 INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2010-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120046266-A1 | RESORCINOL DERIVATIVES AS HSP90 INHIBITORS | HSP90AB1, HSP90AA1, HSP90AB2P | EPHX1 2034/4885MAPT 84/4885POLB 2469/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.